Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07245628 · ClinicalTrials.gov registry record · Early Phase 1
A Trial of Self-Adjusted Nitrous Versus Placebo During Office Vasectomy
A Early Phase 1 study of Vasectomy, sponsored by Alexandra J. Berger Eberhardt, MD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07245628: Recruiting Early Phase 1 study of Vasectomy, sponsored by Alexandra J. Berger Eberhardt, MD.
NCT07245628 is a Early Phase 1 study of Vasectomy that is actively recruiting participants, run by Alexandra J. Berger Eberhardt, MD. The registered enrollment target is 50 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07245628, a Early Phase 1 study of Vasectomy, is actively recruiting participants, sponsored by Alexandra J. Berger Eberhardt, MD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to see if nitrous oxide is safe and effective to use during during vasectomies performed in a clinic/in-office setting. This trial will compare self-administered nitrous oxide versus a placebo (oxygen) during office vasectomy. The main questions it aims to answer are: * Whether self-administered low dose (20-45%) nitrous oxide (SANO) reduces intraoperative anxiety and catastrophizing during office vasectomy. * To examine whether SANO reduces intraoperative pain or alters procedure duration, the rate of adverse events, or urologists' perception of ease and patient tolerance of the procedure. Participants will be asked to complete multiple surveys pre-procedure, intra-procedure, and post-procedure.
Primary Outcome
Measuring the mean difference in Visual Analog Scale for Anxiety (VAS-A) during the vasectomy procedure and the Situational Pain Catastrophizing Scale (S-PCS) immediately after the vasectomy procedure, comparing those receiving and not receiving self-administered low dose nitrous oxide. Intra-Procedure (Immediately After Injection of Local Anesthesia) Visual Analog Scale for Anxiety (VAS-A) (Zero is equivalent to no anxiety and 10 indicates the worst anxiety) Intra-Procedure (In Between Left a
Conditions Studied
Interventions
- DRUG Oxygen
- DRUG Nitrous Oxide
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2030-05-01 |
| Phase | Early Phase 1 |
What NCT07245628 shows while recruiting
NCT07245628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Vasectomy appearing as the primary indexed condition, and to 2 interventions - of which Oxygen is the first listed.
NCT07245628 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07245628 about?
NCT07245628 is a clinical study titled "A Trial of Self-Adjusted Nitrous Versus Placebo During Office Vasectomy". The goal of this clinical trial is to see if nitrous oxide is safe and effective to use during during vasectomies performed in a clinic/in-office setting. This trial will compare self-administered nitrous oxide versus a placebo (oxygen) during office vasectomy. The main questions it aims to answer...
What is the current status of trial NCT07245628?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2025-10-20. Estimated completion is 2030-05-01.
What conditions does trial NCT07245628 study?
This clinical trial studies the following conditions: Vasectomy.
What interventions are being tested in trial NCT07245628?
The interventions under investigation include: Oxygen (DRUG), Nitrous Oxide (DRUG).
Who is sponsoring clinical trial NCT07245628?
This trial is sponsored by Alexandra J. Berger Eberhardt, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07245628 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vasectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07245628's enrollment target sits among peer trials
50 493rd of 2000 higher than 1,468 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI